Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (ucb 44212) at Individualized Doses Up to a Maximum of 160mg/Day in Refractory Epileptic Patients.

Trial Profile

Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (ucb 44212) at Individualized Doses Up to a Maximum of 160mg/Day in Refractory Epileptic Patients.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Seletracetam (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 23 Nov 2006 Status change from Initiated to withdrawn prior to recruitment
    • 17 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top